<DOC>
	<DOCNO>NCT00004094</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy treat patient previously untreated advanced cancer mouth , pharynx , larynx .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Previously Untreated Advanced Cancer Mouth , Pharynx , Larynx</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate activity induction chemotherapy carboplatin paclitaxel follow concurrent fluorouracil , hydroxyurea , paclitaxel , hyperfractionated radiotherapy term response rate , pattern failure , time progression , overall survival patient previously untreated advanced oral , pharyngeal , laryngeal cancer . - Assess treatment regimen term pattern degree clinical acute , cumulative , chronic toxic effect patient population . - Assess rate organ preservation resectable patient treat regimen . - Evaluate quality life , organ function , incidence second primary tumor patient treat regimen . - Assess rate complication subcutaneously implant IV infusion catheter patient treat regimen . OUTLINE : Patients receive induction chemotherapy comprise paclitaxel IV 3 hour follow carboplatin IV 30 minute weekly 3 week . Treatment repeat every 4 week 2 course . At 1-2 week completion induction chemotherapy , patient receive oral hydroxyurea every 12 hour day 1-6 , fluorouracil IV continuously day 1-5 , radiotherapy twice daily day 1-5 , paclitaxel IV 1 hour day 2 . Treatment repeat every 2 week 5 course . Patients residual nodal disease initially stag nodal disease absence macroscopic residual disease undergo neck dissection completion chemoradiotherapy . Patients residual disease primary site undergo complete excision disease . Patients disease progression disease recurrence consider conventional surgical management . Quality life assess every 3 month 6 month , every 6 month 1.5 year , annually thereafter . Patients follow monthly 1 year , every 2 month 1 year , every 3 month thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell poorly differentiate carcinoma , lymphoepithelioma head neck Stage III carcinoma base tongue hypopharynx Stage IV carcinoma oral cavity , pharynx ( include nasopharynx , oropharynx , hypopharynx ) , larynx No distant metastasis Measurable disease desirable Clinically disease free prior surgery allow PATIENT CHARACTERISTICS : Age : 15 80 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No clinically significant cardiomyopathy congestive heart failure Pulmonary : No clinically significant pulmonary dysfunction Other : No severe baseline neurologic deficits No uncontrolled active infection curable without treatment cancer No sensitivity Cremophor EL Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Incisional excisional biopsy organ spar procedure ( e.g. , debulking airway compromise tumor neck dissection ) patient exist primary tumor allow No 3 month since prior nonbiopsy procedure</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>